Background: Although in situ pathological studies and in vivo magnetic resonance (MR) investigations have shown that axonal injury can be significant in the early stages of multiple sclerosis (MS), diffuse axonal injury is generally considered a secondary event. Cerebral axonal damage can be specifically assessed in vivo by measuring levels of brain N-acetylaspartate (NAA, a specific index of axonal integrity detected by MR spectroscopy). Other new MR measurements such as magnetization transfer ratio (MTr) or computed estimation of brain volume can provide less specific indexes of tissue damage.

Objective: To determine whether diffuse axonal and tissue injury is present in patients with definite MS who do not show clinically significant disability.

Methods: We measured brain NAA levels (normalized to creatine [Cr]), MTr values, and cerebral volumes in patients with definite MS who had low T2-weighted MR imaging lesion volumes and no clinical disability, and also in age-matched healthy control subjects.

Results: Values of central brain NAA/Cr and MTr in normal-appearing white matter were significantly lower in the MS patients than in controls (P<.001). In contrast, total brain volumes were not significantly different between these groups. Similar results were found for MS patients with early disease (duration, <3 years) and with a particularly low cerebral T2-weighted MR imaging lesion load (< or = 2 cm(3)).

Conclusions: Cerebral NAA/Cr and MTr values are diffusely decreased in MS patients with early disease, low demyelinating lesion load, and no significant disability. This suggests that axonal and/or tissue injury begins very early in the course of MS and might be at least partially independent of cerebral demyelination.

Download full-text PDF

Source
http://dx.doi.org/10.1001/archneur.59.10.1565DOI Listing

Publication Analysis

Top Keywords

diffuse axonal
12
axonal tissue
8
tissue injury
8
injury patients
8
multiple sclerosis
8
axonal injury
8
patients definite
8
axonal
5
injury
4
patients
4

Similar Publications

Biomarkers.

Alzheimers Dement

December 2024

Laboratory of Clinical Investigation, National Institute on Aging, Intramural Research Program, Baltimore, MD, USA.

Background: Neurite degeneration is increasingly suspected to represent a causal feature of mild cognitive impairment (MCI) and Alzheimer's disease (AD). Therefore, sensitive and specific imaging biomarkers of neuronal degeneration are needed to elucidate the mechanisms underlying cognitive impairment in MCI and AD. However, the recently developed Neurite Orientation Dispersion and Density Imaging (NODDI) MRI technique, used to measure the neurite density index (NDI), has some limitations.

View Article and Find Full Text PDF

Background: Diffusion magnetic resonance imaging (dMRI) permits characterizing differences in white matter microstructure associated with amnestic mild cognitive impairment (aMCI) and Alzheimer's dementia (AD). However, most dMRI measures aggregate signals across multiple axonal fiber populations with varying spatial orientations, which limits the sensitivity and specificity of clinical diagnosis. To overcome this shortcoming, we estimated fiber density (FD) measures, independently from crossing fiber populations, and extracellular cerebral spinal fluid (CSF).

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Laboratory of Clinical Investigation, National Institute on Aging, Intramural Research Program, Baltimore, MD, USA.

Background: Neuroimaging-based evidence suggests that changes in cerebral tissue determinants, including axonal density and myelin content, are associated with aging and neurodegenerative diseases. While neuroimaging markers show strong association with physiological changes, direct validation of their specificity remains challenging. Histology provides useful information for validation, however, faces limitations including denaturation of the sample during preparation.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Munich Cluster for Systems Neurology (SyNergy), Munich, Bavaria, Germany.

Background: In Alzheimer's disease (AD), cortical tau aggregation is a strong predictor of cortical brain atrophy as shown by MRI and PET studies, particularly driving the degeneration of neuronal somata in the grey matter. However, tau's physiological role is to stabilize microtubules within axons in the brain's white matter (WM) pathways. Therefore, tau's white-to-grey-matter translocation and aggregation in neurofibrillary tangles close to neuronal somata may induce WM degeneration through destabilization of axonal microtubule integrity.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Douglas Mental Health University Institute, Montreal, QC, Canada.

White matter hyperintensities (WMHs) are frequently observed in ageing individuals, and have a higher prevalence in neurodegenerative disorders such as Alzheimer's disease. Ex-vivo assessments of the microstructural alterations within WMHs have reported heterogeneous tissue alterations, with demyelination, axonal loss, and inflammation presenting with various degrees of severity. There is a crucial need to better assess the severity of WMH microstructural alterations in vivo, in particular with the emergence of anti-amyloid immunotherapies and the associated risk of Amyloid Related Imaging Abnormalities (ARIAs) in individuals with comorbid vascular disease.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!